Eli Lilly and Company (NYSE:LLY) Position Boosted by Fiduciary Family Office LLC

Fiduciary Family Office LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 9.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,132 shares of the company’s stock after buying an additional 188 shares during the quarter. Fiduciary Family Office LLC’s holdings in Eli Lilly and Company were worth $1,889,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MinichMacGregor Wealth Management LLC lifted its stake in Eli Lilly and Company by 6.7% during the third quarter. MinichMacGregor Wealth Management LLC now owns 730 shares of the company’s stock worth $647,000 after purchasing an additional 46 shares during the period. Crestwood Advisors Group LLC increased its position in shares of Eli Lilly and Company by 0.4% during the 3rd quarter. Crestwood Advisors Group LLC now owns 35,686 shares of the company’s stock worth $31,616,000 after purchasing an additional 140 shares in the last quarter. Global Wealth Management Investment Advisory Inc. boosted its position in Eli Lilly and Company by 1.0% in the third quarter. Global Wealth Management Investment Advisory Inc. now owns 6,139 shares of the company’s stock valued at $5,438,000 after buying an additional 58 shares in the last quarter. Heritage Investors Management Corp grew its stake in Eli Lilly and Company by 13.5% during the third quarter. Heritage Investors Management Corp now owns 1,149 shares of the company’s stock worth $1,018,000 after buying an additional 137 shares during the last quarter. Finally, Pittenger & Anderson Inc. grew its position in Eli Lilly and Company by 13.8% during the 3rd quarter. Pittenger & Anderson Inc. now owns 1,285 shares of the company’s stock worth $1,138,000 after acquiring an additional 156 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Barclays cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Citigroup raised their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Finally, Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,008.41.

Eli Lilly and Company Trading Down 0.9 %

Shares of Eli Lilly and Company stock traded down $7.29 during trading on Tuesday, reaching $798.85. 908,639 shares of the stock were exchanged, compared to its average volume of 3,050,002. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The firm has a market cap of $758.36 billion, a price-to-earnings ratio of 86.46, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43. The stock’s fifty day moving average is $908.15 and its 200 day moving average is $867.39. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the company posted $0.10 EPS. Eli Lilly and Company’s revenue was up 20.4% on a year-over-year basis. As a group, equities research analysts expect that Eli Lilly and Company will post 13.23 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.